



Annual Report

2021

The central resource for
the Swiss biotech industry



Impressum

Publisher: Swiss Biotech Association
Concept and text: Sabine Bamert, Michael Altorfer, Swiss Biotech Association
Layout: Luis Argüello, guay | corporate media design
Pictures: Swiss Biotech Association
Print: Schmid-Fehr AG
Climate-neutral print on wood-free, matt coated paper



Contents

Two decades with the Swiss Biotech Association	4
Record R&D investments and 88 new members	6
Swiss Biotech Ventures platform	7
Working on offering, funding and networking	8
Swiss Biotech Success Stories	10
Award winners 2019	12
Award winners 2020	13
Award winners 2021	14
Award winners 2022	
Genedata	16
Etienne Jornod	18
In the media	20
Services and publications	21
Financial statements 2021	22
Development in numbers	25
Partner network	26
Our members	28
About the Swiss Biotech Association	32
Preferential business solutions for members	34
Supporting the Swiss biotech hub: Objectives for 2022	37

Two decades with the Swiss Biotech Association

I have had the privilege to be a member of the board of the Swiss Biotech Association for the last 20 years and president for the last nine. The association has grown and matured over this period, and I would like to take this opportunity to highlight some of the key achievements.



Dominik Escher
President Swiss Biotech Association from
2013 to 2022

When I joined the board, the association had a booth at many national and international conferences. This was a great way to promote Switzerland as an attractive place for biotech and it was always a nice spot to meet at large conferences. This was a good achievement given the small team and limited resources we could afford at the time. But we wanted to do so much more for our members.

The key to achieving this was to grow the team but financial resources were very limited. We always had a tight budget and the board worked in an honorary capacity. At first, the association received federal support through projects run with the Commission for Technology & Innovation or the National Thematic Network. But these projects were limited to one or two years, making financial planning difficult. We wanted to finance the association with a longer term perspective allowing for financial stability and growth.

Today, the association is mainly financed through member fees. Membership fees allowed us to grow the management team from 0.6 full time employees to 3.5 today. Growing the team meant that we could start to expand our activities and by doing so, we enhanced the relevance of the Swiss Biotech Association to the industry, creating a virtuous circle of service and growth.

We launched the Swiss Biotech Day to complement our annual general meeting. Our aim was to bring together Swiss biotech entrepreneurs and to foster networking in our industry. In 2021, we welcomed close to 900 participants, not only from biotech companies but also the pharma industry and venture capital firms, representing 27 different countries. Over 20 years this event has grown to become the largest biotech event in Switzerland.



Alongside these activities we started to add member benefits: corporate promotion through the association, a job portal, publishing news from our members, negotiating discounts at many conferences and better prices for employee benefit solutions and insurance, offering discounts for lab and other supplies, as well as discounted access to publications.

We were also lobbying and working to improve the framework conditions for Swiss biotech companies. Back in 2016, we were pushing back against the new taxation rules for start-ups. More recently we have been campaigning against the initiative to ban animal testing and clinical trials.

Another major new feature has been the launch of success stories to promote biotech and make our industry more visible. Every year, several case studies are selected to show the public how biotech companies contribute to helping patients and making a valuable and significant contribution to the Swiss economy.

All of this work over the last 20 years has supported the continued growth and relevance of the association. So much so that by the end of last year we had achieved a new record of 364 members in the Swiss Biotech Association.

Looking back on this 20 year journey, I would like to thank all of my colleagues for the many enjoyable meetings and interactions. The association still has a lot to do. Issues - such as the decreasing numbers of early clinical trials in Switzerland, funding gaps and a limited talent pool - mean that the association and its work remain critically relevant to the ongoing success of the industry.

In the future, I look forward to supporting Swiss biotech companies through direct

engagement and I wish the board and the management team lots of success in directing the Swiss Biotech Association through the next 20 years.

I am sure Switzerland will remain one of the most successful countries for our industry.

Sincerely yours,

Dominik Escher
President Swiss Biotech Association

Record R&D investments and 88 new members



The Covid pandemic continued to be a dominant factor in 2021, and Switzerland was again one of the countries that contributed innovative and valuable solutions. While the development and manufacture of vaccines and diagnostics were the focus in 2020, in 2021 Humabs Biomed/Vir Biotechnology and Molecular Partners succeeded in developing effective Covid-specific therapeutics.

At the end of 2020, we had cautioned that the Covid pandemic could jeopardize the development of the Swiss biotech pipeline and innovation power. While some delays were inevitable, there was no major slowdown in terms of financing and R&D investments. In fact, 2021 turned out to be another strong year with a capital influx of more than CHF 3.3 billion and R&D record investments exceeding CHF 2.5 billion.

Overall, the Swiss biotech industry remained remarkably robust:

- ▶ Employment in R&D biotech companies increased by almost 10% in 2021
- ▶ Pharma and biotech exports also rose by about 10% to around CHF 110 billion, contributing roughly 42% to the Swiss exports
- ▶ Anaveon and Numab Therapeutics proved that the private financing market in Switzerland is strong and supports large financing rounds exceeding CHF 100 million
- ▶ The very successful IPOs of SOPHiA GENETICS and VectivBio, which together raised close to CHF 400 million, also proved that public market access was alive and well

In 2020, we could not organize the Swiss Biotech Day due to the constraints imposed by the Covid pandemic. But in September 2021 we found back to the established live format. It was a roaring success with a record attendance of more than 850 participants. Despite the pandemic, about 30 percent of attendees came from abroad, representing some 27 nations.

In 2021, 88 new members joined the Swiss Biotech Association, bringing total membership to 364 companies, the largest in the history of the association. This strong and

increased support helps us to deliver on our mission with far greater impact:

- ✓ Launching the **Swiss Biotech Ventures** platform to match biotech ventures, investors, and pharma partners
- ✓ Expanding the partner network of the **SBA Academy** platform
- ✓ Maintaining an effective networking presence through the online '**Swiss Pavilions**' at **BIO US** and **BIO Europe**, and through free access to the BiotechGate Digital Partnering for our members
- ✓ Securing membership in the **health policy commission of economiesuisse**
- ✓ Granting **Swiss Biotech Success Stories Awards** to Bachem, Basilea, EsbaTech, Lonza, and Novimmune


Our objectives for 2022 are outlined on page 37 onwards. Please reach out to board members and the management team (see p. 32) with your feedback, and support us in providing a strong voice for the Swiss biotech ecosystem.


Yours faithfully,

Michael Altorfer
CEO

Swiss Biotech Ventures platform

In 2021, the unique Swiss Biotech Ventures platform was successfully launched at the Swiss Biotech Day, facilitating the funding, partnering, and licensing between biotech companies, investors, and pharma companies. Visit ventures.swissbiotech.org to profile your venture, list yourself as an investor or industry partner, and to find attractive partnering and investment opportunities.

SIGN IN



I am an investor or industry partner

Get an exclusive access to Swiss Biotech Ventures.

Identify ventures in your areas of interest, and contact or follow up your favourite projects.


[Create an account \(free\)](#)[More information](#)


I am the leader of a Swiss biotech venture

Make your academic project or spin-off visible to trusted investors and industry partners.




Increase your chances of successful funding or partnership, now or in the future.

[Create an account \(free\)](#)[More information](#)





Platform operated by
Swiss Biotech Association



Working on offering, funding and networking

The Covid pandemic also dominated 2021. However, the Swiss Biotech Association continued to provide support for its members and the Swiss biotech industry.

Launch of the unique Swiss Biotech Ventures platform: Matching biotech investment opportunities with investors at ventures.swissbiotech.org

Swiss Biotech Association becomes a member of the health policy commission of [economie.suisse](https://economie.suisse.ch)

Successful comeback of the Swiss Biotech Day with 850 guests enjoying networking opportunities at Switzerland's leading biotech conference and the industry event of the year

Publication of the Swiss Biotech Report 2021 demonstrating the exceptional performance of the Swiss biotech industry and a strong fundraising of CHF 3.4 billion



Numerous association presentations and partnering events throughout the year, including presence at the Ilmac in Basel and panel participation at the Sachs investor conference

Media release and coordinated global approach to oppose intellectual property waiver

Launch of the leading Swiss Biotech Directory 2021 with more than 1,000 companies


Expanding our presence to Basel with a representation at the Basel area chamber of commerce





Conducting interviews with national and international media to highlight the strong contribution of Switzerland to mitigate the impact of the Covid pandemic

Presenting Swiss biotechs virtually in the Swiss Pavilion with Switzerland Global Enterprise at BIO International and Europe conventions



Webinar on new funding schemes stimulating science-based innovation on the impulse program by Innosuisse and the subordinated loan guarantee program by Basel-Stadt

Cooperation with Euresearch to communicate possibilities for Swiss participation in Horizon Europe

Supporting efforts to strengthen and position Switzerland as a manufacturing country and a leading center in antibiotic research

Regular Swiss Biotech CEO updates, the annual meeting, and biotech CEO networking events with investors and multi-national pharma companies



Exposing the negative impact of the people's initiative to ban clinical trials and animal testing by communicating to the public and the network



SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Swiss Biotech Success Stories demonstrate the power and potential of the industry

The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.



Switzerland is one of the world's leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 50,000 jobs and, together the biotech and pharmaceutical industries, account for more than 40% of Swiss exports.

To make the industry's impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational,

medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

"It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive," says Michael Altorfer, CEO of the Swiss Biotech Association. "Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech."

12 success categories

- ▶ Completed achievement with lasting impact
- ▶ Scientific breakthrough
- ▶ New technology
- ▶ Strong impact on society
- ▶ Product approval and sustainable revenues
- ▶ Important IP, innovative deal-making, acquisition
- ▶ Involvement of one or more Swiss citizens
- ▶ Swiss-based company / institution
- ▶ Creation of jobs in Switzerland
- ▶ Other aspect with a direct link to Switzerland
- ▶ Enabler for the biotech industry
- ▶ Swissness: Think global, made in Switzerland



Luca Bolliger
President of the jury
Vice President
Swiss Biotech
Association



Patrick Aebischer
Entrepreneur
Former President
of EPFL



Stefanie Flückiger-Mangual
Chief Executive Officer
and Co-Founder Tolremo



Gabrielle Gache
President Swiss Health-
care Licensing Group



Ulrich Geilinger
Co-Founder and Senior
Partner, Head of Private
Equity HBM Partners



Seraina Gross
Business journalist
Handelszeitung



Daniela Marino
Chief Executive Officer
and Co-Founder Cutiss



Jürg Zürcher
Expert and EY senior
advisor in the biotech
field



Thomas Staffelbach
Secretary of the jury
TS Kommunikation

A big thank you to our partners

Sponsors



The Swiss Biotech Success Stories Awards are also supported by



Basel-Stadt | INNOTIO | TS Kommunikation

SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Award winners 2019



- ▶ Headquartered in Zug, Biogen has been a key stimulus and model for the biotech industry. Its best-selling drug for multiple sclerosis or its Alzheimer's candidate, as well as the new production facilities in Luterbach, creating 600 new jobs, are proof of Biogen's success.



- ▶ The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.



- ▶ Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.



- ▶ The advanced technologies in protein expression by Selexis allow biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. Almost one hundred drug candidates in clinical development and three commercial products utilize the technologies of the Plan-les-Quates-based company.



- ▶ This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.



Award winners 2020



- ▶ Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.



- ▶ Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Over a million patients benefit from their therapies every year.



- ▶ Helsinn, an important employer in Ticino, has a broad portfolio of marketed cancer care products and a deep development pipeline. It has built significant R&D and manufacturing capacities, also advances patient care and supports healthcare innovation with its investment fund.



- ▶ The trio of foundations has been supporting biotech startups with great success for more than 10 years, thereby making a significant contribution to the growth of the Swiss biotech industry. They share the nomination for the Swiss Biotech Success Stories Award.



Werner Arber

- ▶ Werner Arber, Swiss microbiologist and geneticist, won the 1978 Nobel Prize in Physiology or Medicine for his discovery of restriction endonucleases. His groundbreaking research in the field of molecular genetics was instrumental in the development of biotechnology.



SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Award winners 2021

BACHEM

- ▶ Bachem is a leading manufacturer of peptides and oligonucleotides. The company has grown over 50% in the last five years and now offers more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides. Its investment plans call for the investment of over USD 400M to continue to pursue its growth strategy.



- ▶ Basilea Pharmaceutica is a leader in targeted oncology small molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has launched two anti-infective treatments: Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole), an antibiotic for severe hospital bacterial infections.



- ▶ ESBATEch, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATEch platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.

Lonza

- ▶ Lonza is a global leader in contract development and manufacturing services with strong R&D capabilities and world-class facilities across five continents. In 2020, Lonza supported more than 820 pre-clinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules.



- ▶ Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.

Find more information at [swissbiotech.org/success-stories](https://www.swissbiotech.org/success-stories)



Open up your network

To ensure that the Swiss Biotech Success Stories will be visible around the globe in many locations, media and events, help us with your network and distribution power.



Let us know if you have contacts in your network who could benefit from the insight into Swiss Biotech Success Stories, and are curious to learn more about the stunning accomplishments of entrepreneurs in this competitive industry.

Interested parties could be: Your customers, suppliers, partners, a journalist, an investor, your company's communication unit, your follower base on social media, your favorite politician, an event platform dedicated to life science, your rotary club colleagues or any other possibility, that could help to promote these success stories.

Share with us your suggestions for spreading the word by email to success@swissbiotech.org or use the QR code to get to our online form.



SWISS BIOTECH SUCCESS STORIES

Award winner 2022



Genedata is the globally leading provider of enterprise software for digitalizing data-rich and complex biopharmaceutical R&D processes. Incorporating extensive biopharma R&D domain knowledge, Genedata software helps biopharmaceutical organizations to streamline workflows, increase research automation, improve experimental data quality, and maximize the ROI in R&D expenditure, which results in innovative biotherapeutics reaching patients faster.

Founded in 1997 by Othmar Pfannes, Ph.D., Genedata is privately owned and headquartered in Basel, Switzerland. Organic growth and a strong commitment to its employees are the cornerstones of Genedata's 25-year history.

With more than 300 employees and offices strategically located throughout Europe, the USA, and Asia, Genedata works closely with global industry leaders to help them deliver innovative biotherapeutics, vaccines, and cell & gene therapies to patients more efficiently.

Today, over 200 R&D institutions rely on the Genedata Biopharma Platform, including all top-25 biopharma companies worldwide.

Knowledge



- ▶ Experienced Global Market Leader – Established in 1997 & privately owned with +300 people in Basel, Boston, London, Munich, San Francisco, Singapore, and Tokyo
- ▶ Innovative Enterprise Platform – Scalable and open built-for-purpose E2E platform; streamlines and automates data-rich & complex R&D processes out-of-the-box
- ▶ Unique Domain Expertise – In-depth biopharma R&D knowledge ensures delivery of integrated solutions aligned with industry best practices
- ▶ Marquee Customer Base – Increasing R&D efficiency and driving innovation with biopharma R&D leaders around the globe via long-term relationships
- ▶ Successful Partnerships Worldwide – Flexible and collaborative business model accelerates digital transformation to maximize ROI


Success Categories

- ★ Completed achievement with lasting impact
- ★ New technology
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen

Core Team



Othmar Pfannes
Ph.D.
CEO & Founder



Hans Peter Fischer
Ph.D.
Director



Peter Haberl
Ph.D.
Director



Stephan Heyse
Ph.D.
Director



Kurt Zingler
Ph.D.
Director

Genedata Biopharma Platform



The Genedata Biopharma Platform is the market leading solution that digitalizes biopharmaceutical R&D processes and enables an R&D revolution driven by artificial intelligence approaches to generate the precision medicines of the future.



Enables Innovation Through Better Insights

Accelerates Workflows Through AI-driven Automation

Improves Probability of Success Through Better Data Quality

Increases Clinical Trial Efficiency Through Better Integration

- ★ Swiss based company
- ★ Creation of jobs in Switzerland
- ★ Other aspects with a direct link to Switzerland
- ★ Swissness: Think global, made in Switzerland



Organized by
**Swiss Biotech
Association**

SWISS BIOTECH SUCCESS STORIES

Award winner 2022



Etienne Jornod

Etienne Jornod spent his entire career at Vifor-Galenica Group where he was Executive Chairman until early 2020. Since October 2020, he is Executive Chairman and Co-Owner of OM Pharma.



Trust is the basis of any collaboration, therefore of any project
Performance & Deliver what we promise creates trust
To succeed we must be honest, transparent and love people



**VIFOR
PHARMA**

Revolutionizing Iron Sucrose

The development of an injectable medication to treat iron deficiency anemia in patients with chronic kidney disease marked the beginning of Etienne Jornod's entrepreneurial success at Vifor Pharma.



Developing Ferric Carboxymaltose

This iron success was followed by the development of a novel iron complex, enabling controlled delivery of iron to target tissues throughout the body.



**VIFOR FRESENIUS MEDICAL CARE
RENAL PHARMA**



This Joint Venture with Fresenius-FMC, in which Etienne Jornod was extensively involved, resulted in the successful launch of Mircera® in the US in partnership with Roche, and has attracted new licensed products in the field of dialysis: Rayaldee®, Tavneos®, Kapruvia®, Vadadustat®.

Success Categories

- ★ Completed achievement with lasting impact
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen
- ★ Swiss-based company/institution

Transitioning to OM Pharma



When Etienne Jornod decided to leave, Vifor-Galenica Group has been able to deliver 25 consecutive times a double-digit growth in net profit and increase the value of its share from CHF 3.40 to CHF 185.25, with a total value increasing from MCHF 220 to MCHF 1,200 from 1995 to 2019.

During his tenure, the company has improved the lives of millions of patients and created thousands of jobs.

Who is OM Pharma

OM Pharma is a global biopharmaceutical company, leader in the prevention of recurrent respiratory and urinary tract infections. In October 2020, Etienne Jornod bought it from Vifor Pharma with his friends.



Its leading products Broncho-Vaxom® and Uro-Vaxom® are bacterial lysates, composed respectively of 21 and 18 pathogen bacterial strains. Manufactured in Geneva, they are distributed in more than 100 countries across the world, via an established, international network of partners.



OM Pharma employs around 450 people globally and has a strong presence in Switzerland, with 350 people in Geneva (Global headquarters & biotech center).

The New OM Pharma's Vision

With the New OM Pharma project, Etienne Jornod aims to create a very innovative biopharmaceutical company based on the unique bacterial lysate expertise developed over decades by OM Pharma.

Encompassing seven projects, the goal of improving patients' lives is central to the development of new medicines for asthma, atopic dermatitis, wheezing and other diseases of the respiratory and urinary systems.



Knowledge & Research

High levels of biotech knowledge and experienced teams with substantial know-how in the manufacturing of immunomodulators based on active bacteria.

Innovative scientific research aiming at extending the use of bacterial lysates for the prevention and treatment of a wide range of immuno-inflammatory diseases, as well as development of new chemical entities.

- ★ Creation of jobs in Switzerland
- ★ Other aspect with a direct link to Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland



Organized by
**Swiss Biotech
Association**


In the media

Key articles and interviews in leading Swiss media supported our goal in making sure that the biotech industry got heard in the public.



Services and publications

One of the Swiss Biotech Association's goals is to enhance the image of the biotechnology industry in Switzerland and abroad, and position it as an important value-adding economic pillar. Besides the Swiss Biotech Success Stories (see p. 10-19), our publications and digital services support the association's drive to expand its impact and strengthen its role as the central resource for the Swiss biotech industry.



Income statement

In CHF	2021		2020	
	Expenses	Income	Expenses	Income
Membership fees		729,500		610,500
National projects ¹		481,231		13,200
Swiss Biotech Success Stories		0		10,000
Swiss Biotech Report		52,000		48,000
Swiss Biotech Directory		22,910		19,201
Increase/decrease bad debt provision		0		-4,700
Total income		1,285,641		696,201
Fees to other associations	26,365		20,676	
International projects	17,037		9,945	
National projects ¹	509,735		45,984	
Swiss Biotech Success Stories	13,717		22,316	
Increase/decrease tied capital "Swiss Biotech Success Stories"	-5,000		-15,000	
Swiss Biotech Sounding Board	5,253		9,102	
Increase/decrease tied capital "Swiss Biotech Sounding Board"	-5,000		-15,000	
Swiss Biotech Report	60,946		50,894	
Swiss Biotech Directory	31,398		41,626	
Website & community platform	99,553		47,269	
Association activities expense	754,004		217,812	
Management fees ²	317,912		295,129	
Accounting & member support	122,468		104,185	
Office rent & administration	26,232		20,534	
Consulting	13,150		24,604	
Public relations	48,399		51,908	
Other operating expenses	528,160		496,360	
Financial income result		-3,914		-299
Income from previous reporting periods		16,501		-8,082
Tax expenses		378		500
Net profit/loss for the year		15,686		-26,852

¹ In 2020 we had to cancel the Swiss Biotech Day due to the Covid-19 pandemic. While costs were incurred to plan and prepare, no income was generated

² Management fees related to events and promotional products are directly booked to the respective project

Balance sheet

In CHF	Balance Sheet 31.12.2021		Balance Sheet 31.12.2020	
	Assets	Liabilities	Assets	Liabilities
Assets				
Cash and cash equivalents	233,314		246,800	
Accounts receivable	22,019		25,885	
Accrued income & prepaid expenses	16,590		11,765	
Total assets	271,923		284,451	
Liabilities				
Accounts payable		36,064		49,967
Accrued expenses & deferred income		65,360		69,671
Association equity		131,239		131,239
Tied capital for SBA Success Stories		10,000		15,000
Tied capital for SBA Sounding Board		10,000		15,000
Retained earnings		3,575		30,426
Net result of the year		15,686		-26,852
Total liabilities		271,923		284,451

Auditor's report



Phone +41 44 444 35 55
Fax +41 44 444 35 35
www.bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

Report of the statutory auditor on the limited statutory examination to the general meeting of

Swiss Biotech Association (SBA), Zurich

As statutory auditor, we have examined the financial statements (balance sheet, income statement and notes) of Swiss Biotech Association (SBA) for the financial year ended 31 December 2021.

These financial statements are the responsibility of the association board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of company personnel and analytical procedures as well as detailed tests of company documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the articles of association.

Zurich, 3 February 2022

BDO Ltd



Manuel Lüthi

Licensed Audit Expert



ppa. Niklaus Stamm

Auditor in Charge

Licensed Audit Expert

Enclosure
Financial statements

Development in numbers

In 2021, 88 members joined the Swiss Biotech Association, a new record. Our website, newsletters and mailings provide an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry. As in the past years, the number of newsletter subscribers and website visitors increased again.



Partner network

National and international partnerships of the Swiss Biotech Association help us leverage our impact. They strengthen our voice and enable us to provide Swiss biotech stakeholders with privileged information and networking opportunities.

Optimizing framework conditions for Swiss biotech companies

- ▶ [economiesuisse](#)
- ▶ [EuropaBio](#)
- ▶ [International Council of Biotech Associations](#)
- ▶ [Interpharma](#)
- ▶ [scienceindustries](#)
- ▶ [Swiss Coordination Committee for Biotechnology](#)

Fostering international collaborations & trade



- ▶ [BIO Deutschland](#)
- ▶ [Biotechnology Innovation Association \(UK\)](#)
- ▶ [SwedenBIO](#)
- ▶ [Europe-Taiwan Biotech Association](#)
- ▶ [Italian Trade Agency](#)
- ▶ [Japan Bioindustry Association](#)
- ▶ [Korea Trade-Investment Promotion Agency](#)
- ▶ [SwedenBIO](#)
- ▶ [Swiss Business Hubs](#)
- ▶ [swissnex](#)

Promoting Switzerland's competitive advantages

- ▶ [Agire](#)
- ▶ [Basel Area Business & Innovation](#)
- ▶ [Basel Chamber of Commerce](#)
- ▶ [BioAlps](#)
- ▶ [Canton of Vaud Chamber of Commerce and Industry](#)
- ▶ [Farma Industria Ticino](#)
- ▶ [Greater Geneva Bern Area](#)
- ▶ [Greater Zurich Area](#)
- ▶ [Life Sciences Cluster Basel](#)
- ▶ [St. Gallen Bodensee Area](#)
- ▶ [Switzerland Global Enterprise](#)

Connections to investors & non-dilutive funding opportunities

- ▶ [Euresearch](#)
- ▶ [Innosuisse](#)
- ▶ [Sachs Associates](#)
- ▶ [SECA](#)
- ▶ [SIX](#)
- ▶ [Swiss Healthcare Startups](#)
- ▶ [Venture Kick](#)





Swiss Biotech Association Academy

- ▶ Basel Area Business & Innovation
- ▶ CTC Resourcing Solutions
- ▶ DIA
- ▶ European Center of Pharmaceutical Medicine
- ▶ Euresearch
- ▶ EPFL
- ▶ Henri B. Meier Unternehmensschule - Universität St. Gallen
- ▶ Lorocho
- ▶ siteminsel
- ▶ Swiss HLG
- ▶ Swiss Institute of Bioinformatics
- ▶ Università della Svizzera italiana
- ▶ Universität Bern
- ▶ University of Applied Sciences and Arts Northwestern Switzerland
- ▶ Venturelab

Preferential business solutions

- ▶ BioCentury (info, analysis and data for biotechs)
- ▶ Helvetia (business insurance)
- ▶ ProcEurope – European Life Sciences Purchasing Consortium (lab supplies)
- ▶ LubioScience (research reagents & lab supplies)
- ▶ Springer Nature (scientific and technical publisher)
- ▶ Swiss Life (pension fund)
- ▶ More than 100 co-promotion partners organizing events & conventions around the globe

Swiss Biotech Success Stories

- ▶ EY (silver sponsor)
- ▶ Switzerland Global Enterprise (silver sponsor)
- ▶ Gebert Rüf Stiftung, Innotio, Basel-Stadt, TS Kommunikation (supporters)

Swiss Biotech Report

- ▶ biotechnet
- ▶ EY
- ▶ scienceindustries
- ▶ SIX
- ▶ Swiss Academy of Engineering Sciences
- ▶ Swiss Federal Institute of Intellectual Property
- ▶ Swiss National Science Foundation
- ▶ Switzerland Global Enterprise

Links to specialized stakeholder groups

- ▶ biotechnet Switzerland (academia)
- ▶ LS² – Life Sciences Switzerland (life sciences)
- ▶ SimplyScience (young talent)
- ▶ Swiss HLG (business development)

List of members, December 2021



88 members that have joined the association in 2021 are shown in red

<p>4G Clinical B.V. abcDNA GmbH ABCDx SA Aboligix Sàrl AC Bioscience SA AC Immune SA ACM Biosciences AG Acthera Therapeutics AG Activen SA ADC Therapeutics SA Addex Therapeutics Ltd Adiposs Sarl Adolf Kühner AG Advitech Advisory and Technologies S.A. Agidens AG Alentis Therapeutics AG Alitheia Genomics SA Alphastrat GmbH Altasciences Alveolix AG Amal Therapeutics SA AMYRA Biotech AG AnaPath Services GmbH Anaveon AG Anjarium Biosciences AG anteris Helvetia AG Aptissen SA Araris Biotech AG ARTIDIS AG ASC Oncology Schweiz AG Asceneuron SA Assystem Care Switzerland SA Athebio AG Auregen Biotherapeutics SA Avance Basel GmbH Avrion Therapeutics AG Axon Lab AG Baccinex SA Bachem AG BakerHicks AG Baliopharm AG Basilea Pharmaceutica Ltd. BC Platforms AG Becton Dickinson AG BERNINA Biolinvest AG BIDECO AG BioConcept AG BioCopy AG Bioengineering AG Biogen International GmbH BioLingus AG Biolytix AG BioMedPartners AG Biopôle SA Bio-Rad Laboratories AG Biosynth Carbosynth AG Bio-Technopark Schlieren-Zürich BioVersys AG</p>	<p>BISC Global GmbH blsc - bihlmann life science communication Bright Peak Therapeutics AG Bromatech (Suisse) SA Bucher Biotec AG Büchi AG Bühlmann Laboratories AG Cabinet Privé de Conseils s.a. (CPC) Calypso Biotech SA Cancer Research and Biotechnology AG Canlion AG CanVirex AG Carbogen Amcis AG CarthaGenetics Suisse Sarl Catalent Pharma Solutions GmbH Catalyze Switzerland GmbH C-CIT Sensors AG CDR-Life AG CEBIS International Celerion Switzerland AG Celestia Biotech AG Cell Receptor SA cellvie AG Celonic AG Cerbios-Pharma SA Cerdia International GmbH certus molecular diagnostics ag Chemengineering Switzerland AG Cilatus Biopharma Consulting AG CimArk SA Cimeo Therapeutics AG CIS Pharma AG Clemedi AG Clinipace AG Consultants in Science Sarl CORETAG Holding AG Coulter Partners Covance Central Laboratory Services Sarl CRB Group GmbH Creoptix AG CROss Research SA CSEM CSL Behring AG CTC Resourcing Solutions Culture Collection of Switzerland AG Curatis AG CUTISS AG Cytosurge AG Cyxone Switzerland AG D36.ch Sarl Dao Tun GmbH Diaxso AG Debiopharm International SA Deep Breath Intelligence AG deepCDR Biologics AG DINAQOR AG Dr. Remus Muresan Legal Services DrM, Dr. Müller</p>	<p>ECS-Progastrin LAB SA EffRx Pharmaceuticals S.A. Elthera AG Emergent BioSolutions EraCal Therapeutics Ltd Eurofins BioPharma Product Testing Switzerland AG Eurofins Genomics GmbH Evitria AG ExcellGene SA ExpertInova AG Fluidic Analytics Ltd Future Health Pharma GmbH G&L Scientific (Schweiz) GmbH Gain Therapeutics SA GALSER SA GBiotech Sàrl GE Healthcare AG Genedata AG GeNeuro SA Geneva Biotech Center (GBC) SA Genexa AG Genkyotex SA GenSearch Switzerland GlycoEra AG GMT Fine Chemicals SA Gnubiotics Sciences SA HBM Partners AG headcount AG Health Advances GmbH Helsinn Healthcare SA HEMEX AG HEXAGONFAB LIMITED HGF GmbH Homburger AG Humabs BioMed AG Hyperbolic Holdings GmbH IBR Inc., Institute for Biopharmaceutical Research Ichnos Sciences SA ICON Clinical Research (Switzerland) GmbH Idorsia Pharmaceuticals Ltd. IE Life Science Engineering AG ImmunOs Therapeutics AG InCephalo AG Incyte Biosciences International Sàrl Infors AG InnoMedica Holding AG Innovative Sensor Technology IST AG INOFEA AG Inositec AG InsideReg Sarl InSphero AG Integra Biosciences AG InterAx Biotech AG Inthera Bioscience AG IONctura SA Janssen-Cilag AG</p>
--	---	--

Jenal & Partners Biosafety Consulting
 JFG Life Sciences Stiftung
JMP Software, SAS Institute GmbH
Kinarus AG
 KPMG AG
 Labatec Pharma SA
Laevoroc Oncology AG
LAGOSTA SA
LaForce Business Solutions Sagl
LATAM Pharma Innovative Ventures AG
 Laves-Arzneimittel GmbH
 LeadXpro AG
 Life Sciences Executive Search LLC
 Light Chain Bioscience - NovImmune SA
 LimmaTech Biologics AG
Limula SA
 Linkster Therapeutics AG
Lino Biotech AG
 Lonza AG
 Loroch CTLS
 LS Instruments
 LubioScience GmbH
 Lunaphore Technologies SA
 LYO-X GmbH
 Malcisbo AG
Matterhorn Biosciences AG
 Maxia Strategies GmbH
 Maxwell Biosystems AG
 MD Biosciences GmbH
 Med Discovery SA
 MEDExpansion Sàrl
 Medical Trials Analysis Swiss SA
 Memo Therapeutics AG
 Merz/Anteis SA
 MetrioPharm AG
 Micro-Sphere S.A.
 Microsynth AG
 Molecular Partners AG
 Monte Rosa Therapeutics AG
 MUVON Therapeutics AG
MV BioTherapeutics SA
 Mymetics SA
Nagi Bioscience SA
 NBE-Therapeutics AG
 NDA Regulatory Service Switzerland GmbH
 Nemis Technologies AG
 NeoGenomics Laboratories Europe SA
 Neovii Pharmaceuticals AG
 Neurimmune AG
NextImmune AG
Nice & Green SA
Nodes Advisors AG
Noema Pharma AG
 NovaGo Therapeutics AG
 Novaremed AG
 Novartis Pharma AG
Novigenix SA
Novochizol SA
 Numab Therapeutics AG
 ObsEva SA
Occident Group AG
 Oculis SA
 Oculox Technologies SA
OM Pharma Ltd
 OMNI Life Science GmbH
 Omya International AG

Onelife SA
Onward Therapeutics SA
 oprandi & partner romandie sa
 Orion Biotechnology Switzerland
 P&G MedChem AG
 Pall (Schweiz) GmbH
 PAREXEL International (CH) AG
 Peleven AG
 Perseo pharma AG
 Phargentis SA
 Pharma Globe AG
 PharmaBiome AG
 Pharma-Consulting ENABLE
PharmNDev Experts SA
 Pharvaris GmbH
 Philip Morris International
 Philochem AG
 Phoenixus AG
plusbiome AG
PLX Healthcare Services (Schweiz) AG
 Polyneuron Pharmaceuticals AG
PolyPeptide Group AG
 Polyphor AG
 Preclin Biosystems AG
 PreComb Therapeutics AG
 Promega AG
 ProteoMediX AG
 PSI CRO AG
 Pureos Bioventures
 QBDC GmbH
 Quartz Bio SA
Quercis Pharma AG
 Quotient Suisse SA
 RADAR RP Sàrl
 Recordati AG
 Redbiotec AG
 Regen Lab SA
 Rejuveron Life Sciences AG
 Remap Consulting GmbH
 Repertoire Immune Medicines (Switzerland) AG
Resea Biotec GmbH
 Resistell AG
Rhizen Pharmaceuticals AG
 Ridgeline Discovery SA
 Roche Glycart AG
Rockwell Automation Switzerland
 Rowestil Consulting GmbH
Saiba AG
 SAKK
 Santhera Pharmaceuticals (Switzerland) AG
Santerus AG
 Sartorius Stedim Switzerland AG
Saverna Therapeutics AG
 Scailyte AG
 Schmidt Versicherungen Treuhand AG
 SeaGen International GmbH
 Securecell AG
 Selexis S.A.
 Senn Resources AG
 Sferalp SA
 SFL Pharma GmbH
 SGS Analytics Switzerland AG
 SGS Société Générale de Surveillance
 Shimadzu Schweiz GmbH
SICPA SA

Sintetica SA
 Sirius Scientific Consulting AG
 Socorex Isba SA
 Sophia Genetics SA
 SpacePharma SA
SPINOFRIN SA
STALICLA SA
 Stobbe Pharma GmbH
 Strategy Consulting Dr. Rudolf K.Sprüngli
 SunRegen Healthcare AG
 Superlab Suisse AG
 swati AG
 Swiss Biotech Center SA
SWISSAVANS AG
SwissBiotechSolutions
 Swissfillon AG
 SwisSolution Human Capital AG
 Switzerland Global Enterprise
 Swizzard Pharma AG
 SynDermix AG
Syneos Health Switzerland GmbH
 Synple Chem AG
 T3 Pharmaceuticals AG
 Talentmark Life Sciences Consulting GmbH
 Talisto GmbH
TargImmune Therapeutics AG
ten23 Health AG
 The RSA Group
therainnova AG
 Thermo Fisher Scientific Life Technologies
 Tigermend Swiss AG
 Tillotts Pharma AG
Tissuelabs Sagl
 tiventia AG
 TOLREMO therapeutics AG
 Toolpoint for Lab Science
 Topadur Pharma AG
 UCB Pharma AG/UCB Farchim SA
Vaderis Therapeutics AG
 valuationLAB AG
 VectivBio AG
Vector BioPharma AG
 Venture Valuation
 Versameb AG
 Versantis AG
 Vifor Pharma Management Ltd.
Viopas Venture Consulting GmbH
 ViridisGroup Sàrl
 Virometix AG
 VISCHER AG
 Voisin Consulting Life Sciences
VTU Engineering Schweiz AG
Walder Wyss
 Wellmera AG
 Werthenstein BioPharma GmbH
 WuXi AppTec
 Wyss Zurich
Xcenda Switzerland GmbH
 YAFO Capital (Shanghai) Co. Ltd
Zenith Technologies
Zeta CH AG

We enhance the visibility of biotech companies

These members profit from a cost-effective and easy-to-do marketing opportunity. For one year their logos feature on our communication tools. These include the Swiss Biotech Association exhibition booth at renowned conferences, publications, and presentations about the Swiss biotech industry for stakeholders, talents, partners, media, investors, and one-on-one meetings.





Swiss Biotech Association board and management

The board



Dominik Escher
President
Executive Chairman
CDR-Life



Patrick Amstutz
Vice President
CEO
Molecular Partners



Luca Bolliger
Vice President
CEO
abcDNA



Jurgi Camblong
Vice President
CEO
SOPHiA GENETICS



Bettina Ernst
Vice President
CEO
Preclin Biosystems



Ulf Grawunder
Vice President
Managing Partner
Viopas Venture Consulting



Martin Howald
Vice President
Honorary Member
CEO BioConcept



Filippo Riva
Vice President
CEO
Humabs Biomed

The management team



Michael Altorfer
CEO



Sabine Bamert
Head of Communications



Heike Bihlmann
Liaison Basel Area, member
support, special projects



Marta Gehring
Biotech Insight Meetings



Patrick Imwinkelried
Accounting
Wespi & Partner



Carsten Laue
Funding & community
platform



Fabio Napoletano
Head Business Development
Liaison Bern & Ticino



Aditya Yellepeddi
Liaison Romandie

The Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents,

novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.



Our Mission

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.

To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

Developing favorable and competitive framework conditions

- ▶ Creating awareness of the biotech industry's needs and interests with policy makers
- ▶ Advocating a competitive tax system alongside lean and pragmatic regulations
- ▶ Fostering life science education, technology transfer and intellectual property

Attracting talent, know-how and financial resources to drive innovation and growth

- ▶ Promoting and facilitating access to funding opportunities

- ▶ Connecting investors and attractive biotech investment opportunities
- ▶ Facilitating access to national and international talent

Fostering networking through strategic, national and international partnerships

- ▶ Connecting industry stakeholders and life science clusters
- ▶ Organizing and co-promoting national and international life science events
- ▶ Providing access to privileged information through industry platforms and working groups

Promoting the accomplishments of the Swiss biotech industry

- ▶ Disseminating the value-creation of Swiss biotech companies
- ▶ Visualizing the diversity and competitiveness of Swiss biotech companies
- ▶ Presenting innovative products and technologies and their contribution to quality of life


Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (see team on p. 32).

Swiss Life's pension fund

With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.

SWISS
BIOTECH's Life



Helvetia's business insurance

Our members can cover their business risks with Helvetia's individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.

helvetia **A**
Your Swiss Insurer

We offer comprehensive cover for members of the Swiss Biotech Association.

Movable property
Buildings insurance
Buildings liability insurance
Technical insurance




Marine insurance
Assistance
Legal protection
Public and professional liability



LubioScience's portfolio

Our members benefit from special discounts on LubioScience's entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.

LUBIO
SCIENCE
THE REAGENT PLATFORM



ProcEurope's laboratory supplies

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific, by the European Life Sciences Purchasing Consortium.




BioCentury's market research

A complimentary test access to BioCentury's Intelligence platform, as well as discount on the subscription helps our members' executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.



Springer Nature's leading publications


The world's leading scientific and technical publisher Springer Nature offers our members subscription discounts between 25% and 50% for some of their most exciting products.



Save the date!

SWISS BIOTECH DAY 2023

© Swiss Biotech Association



April 24-25, 2023
Congress Center Basel

What you can expect:

- › Meet 850+ senior experts from the life science industry
- › 50+ exhibitors from across Europe
- › Delegations from various regions
- › Swiss Biotech Success Stories Awards
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematically focused panel discussions
- › Pre-scheduled one-to-one partnering meetings
- › General Assembly of the Swiss Biotech Association

Sign in on our website at
www.swissbiotechday.ch
and stay updated about any news.

Media partners:



LABORWELT



BIOCOM®

Supporting the Swiss biotech hub - Objectives for 2022

The 2022 objectives of the Swiss Biotech Association link to one of the four mission pillars (see p. 33) or enhance the financial flexibility and operational effectiveness of the association.



Favorable frameworks

While Switzerland still offers one of the most attractive framework conditions for science-based innovators, the international conditions are becoming increasingly challenging as many nations turn to national and protective measures. Such measures hinder international cooperation and complicate joint R&D. As it becomes more difficult to share results, and additional framework hurdles arise, the speed of biomedical innovation must inevitably slow down. On top of this, reliable IP framework conditions are being challenged.

The Swiss Biotech Association has established a tight network of partners in Switzerland and abroad who are aligned around the shared objective to optimize global framework conditions for biotech startups and SMEs focusing on R&D (see partner organizations on p. 26).

In 2022, we focus on:

- Re-establishing Switzerland's full association with the Horizon Europe R&D program
- Emphasizing the need for high quality animal testing facilities for biotech companies in Switzerland, highlighting the risks associated with outsourcing such testing to other countries
- Opposing the proposed TRIPS (Trade Related Aspects of Intellectual Property Rights) waiver, which aims at weakening the international IP framework and thereby risks undermining biomedical innovation



Talent and finance

The second pillar in our mission focuses on supporting Swiss-based biotech companies in accessing international talents, financial funding, and access to new technologies. When biotech companies have access to these critical resources, they can benefit from the competitive framework conditions that Switzerland offers. In 2022, the Swiss Biotech Association aims to support this mission objective by:

- Building a talent pool platform for the Swiss biotech industry and its partners. The 'Swiss Biotech Orbit' is designed to attract and retain biotech talents and facilitate their matching with open job opportunities
- Further expanding professional education and training through the Swiss Biotech Association Academy platform
- Promoting and expanding the use of our non-public Swiss Biotech Ventures platform to facilitate matching of biotech companies, investors, and pharma partners
- Promoting the SPARKS segment of the Swiss Stock Exchange to facilitate access to capital markets for Swiss and European biotech SMEs
- Expanding the list of partnerships which offer business solutions that reduce operating costs for our members



Networking and information exchange

This year, the Swiss Biotech Day, our flagship networking event, will be held over the course of two days in Basel on May 2-3, 2022. As part of our strategy of constantly expanding our event and trading partner network, we have expanded our co-promotion agreements with life science conferences around the globe, providing members with attractive discounts and presentation opportunities.

In 2022, we plan to:

- Strengthen the Swiss Biotech Day with additional networking opportunities for biotech CEOs, investors and multi-national pharma companies
- Continue to expand the Swiss R&D biotech CEO meeting platform
- Collaborate with the Swiss Private Equity & Corporate Finance Association and Sachs Associates to exploit synergies with biotech investor meetings
- Collaborate with the Swiss Academy of Technical Sciences (SATW) in promoting the potential of industrial biotech and sustainable manufacturing
- Kick off the 'Global Village' platform to invite international delegations to specifically strengthen the bilateral relationship in life sciences between the guest countries and Switzerland

Promotion and awareness

The Swiss biotech industry has demonstrated its innovation power in providing solutions to address the global Covid pandemic. The Swiss biotech hub is recognized as an attractive partner for R&D collaborations, international talents, academic institutions, and industry partners. International investors value the investment opportunities Switzerland can offer in this field.

Nevertheless, the pricing of, and access to therapeutic opportunities continue to be hotly debated. That is why the association highlights the importance of a fair reimbursement for innovators and their investors who bear the risks associated with drug R&D. Such reimbursement is vital to ensure that investors and biotech entrepreneurs alike continue to engage and invest in the development of innovative medical treatment options.


We will continue to effectively present the strength and diversity of the more than 1,000 biotech companies that comprise the Swiss biotech sector. The Swiss Biotech Directory shows that Switzerland has established a very densely populated and highly diversified biotech hub covering all aspects of biotechnology and with a strong international profile.

To support this, in 2022, we will:

- Publish the digital and print edition of the Swiss Biotech Directory
- Publish the Swiss Biotech Report 2022, highlighting the key sources of Swiss innovation
- Present the Swiss Biotech Success Story Award to the 2022 laureates and nominate the 2023 laureates
- Expand the partner network to support industry promotion and raise awareness of Swiss biotech accomplishments and needs

Clear focus on what really matters

Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.



We see the strong growth of our membership base as an expression of trust and a confirmation that we are on the right track.

We encourage you to continue to engage in an active dialogue with us to jointly shape the future of our industry and its framework, and thereby keep Swiss biotech successful and competitive internationally.

Yours faithfully,

Michael Altorfer
CEO



Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
Switzerland

T: +41 44 455 56 78

info@swissbiotech.org
swissbiotech.org